Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression
<p>Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their car...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , , |
| Published: |
2022
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513567574720512 |
|---|---|
| author | Nabeel Abdulrahman (725914) |
| author2 | Meram Ibrahim (14151348) Jensa Mariam Joseph (14151351) Hanan Mahmoud Elkoubatry (14151354) Al-Anood Al-Shamasi (14151357) Menatallah Rayan (14151360) Alain Pierre Gadeau (14151363) Rashid Ahmed (3900679) Hussein Eldassouki (14151366) Anwarul Hasan (1332066) Fatima Mraiche (715733) |
| author2_role | author author author author author author author author author author |
| author_facet | Nabeel Abdulrahman (725914) Meram Ibrahim (14151348) Jensa Mariam Joseph (14151351) Hanan Mahmoud Elkoubatry (14151354) Al-Anood Al-Shamasi (14151357) Menatallah Rayan (14151360) Alain Pierre Gadeau (14151363) Rashid Ahmed (3900679) Hussein Eldassouki (14151366) Anwarul Hasan (1332066) Fatima Mraiche (715733) |
| author_role | author |
| dc.creator.none.fl_str_mv | Nabeel Abdulrahman (725914) Meram Ibrahim (14151348) Jensa Mariam Joseph (14151351) Hanan Mahmoud Elkoubatry (14151354) Al-Anood Al-Shamasi (14151357) Menatallah Rayan (14151360) Alain Pierre Gadeau (14151363) Rashid Ahmed (3900679) Hussein Eldassouki (14151366) Anwarul Hasan (1332066) Fatima Mraiche (715733) |
| dc.date.none.fl_str_mv | 2022-11-22T21:13:52Z |
| dc.identifier.none.fl_str_mv | 10.1007/s11010-022-04411-6 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Empagliflozin_inhibits_angiotensin_II-induced_hypertrophy_in_H9c2_cardiomyoblasts_through_inhibition_of_NHE1_expression/21597393 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biochemistry and cell biology Medical biochemistry and metabolomics Cell Biology Clinical Biochemistry Molecular Biology General Medicine |
| dc.title.none.fl_str_mv | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotective effect. The mechanism by which SGLT-2 inhibitors exert their cardioprotective effect remains unclear. Recent studies have suggested that EMPA exerts its cardioprotective effect by inhibiting the Na+/H+ exchanger (NHE), a group of membrane proteins that regulate intracellular pH and cell volume. Increased activity and expression of NHE isoform 1 (NHE1), the predominant isoform expressed in the heart, leads to cardiac hypertrophy. p90 ribosomal s6 kinase (p90 RSK) has been demonstrated to stimulate NHE1 activity. In our study, H9c2 cardiomyoblasts were treated with angiotensin II (ANG) to activate NHE1 and generate a hypertrophic model. We aimed to understand whether EMPA reverses the ANG-induced hypertrophic response and to elucidate the molecular pathway contributing to the cardioprotective effect of EMPA. Our study demonstrated that ANG-induced hypertrophy of H9c2 cardiomyoblasts is accompanied with increased SGLT-1 and NHE1 protein expression, an effect which is prevented in the presence of EMPA. EMPA reduces ANG-induced hypertrophy through the inhibition of SGLT-1 and NHE1 expression.</p><h2>Other Information</h2> <p> Published in: Molecular and Cellular Biochemistry<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s11010-022-04411-6" target="_blank">http://dx.doi.org/10.1007/s11010-022-04411-6</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_f040c19b183cfd62983a34630346571a |
| identifier_str_mv | 10.1007/s11010-022-04411-6 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21597393 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expressionNabeel Abdulrahman (725914)Meram Ibrahim (14151348)Jensa Mariam Joseph (14151351)Hanan Mahmoud Elkoubatry (14151354)Al-Anood Al-Shamasi (14151357)Menatallah Rayan (14151360)Alain Pierre Gadeau (14151363)Rashid Ahmed (3900679)Hussein Eldassouki (14151366)Anwarul Hasan (1332066)Fatima Mraiche (715733)Biochemistry and cell biologyMedical biochemistry and metabolomicsCell BiologyClinical BiochemistryMolecular BiologyGeneral Medicine<p>Diabetes mellitus (DM)-induced cardiac morbidities have been the leading cause of death among diabetic patients. Recently, sodium-glucose cotransporter-2 (SGLT-2) inhibitors including empagliflozin (EMPA), which have been approved for the treatment of DM, have gained attention for their cardioprotective effect. The mechanism by which SGLT-2 inhibitors exert their cardioprotective effect remains unclear. Recent studies have suggested that EMPA exerts its cardioprotective effect by inhibiting the Na+/H+ exchanger (NHE), a group of membrane proteins that regulate intracellular pH and cell volume. Increased activity and expression of NHE isoform 1 (NHE1), the predominant isoform expressed in the heart, leads to cardiac hypertrophy. p90 ribosomal s6 kinase (p90 RSK) has been demonstrated to stimulate NHE1 activity. In our study, H9c2 cardiomyoblasts were treated with angiotensin II (ANG) to activate NHE1 and generate a hypertrophic model. We aimed to understand whether EMPA reverses the ANG-induced hypertrophic response and to elucidate the molecular pathway contributing to the cardioprotective effect of EMPA. Our study demonstrated that ANG-induced hypertrophy of H9c2 cardiomyoblasts is accompanied with increased SGLT-1 and NHE1 protein expression, an effect which is prevented in the presence of EMPA. EMPA reduces ANG-induced hypertrophy through the inhibition of SGLT-1 and NHE1 expression.</p><h2>Other Information</h2> <p> Published in: Molecular and Cellular Biochemistry<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1007/s11010-022-04411-6" target="_blank">http://dx.doi.org/10.1007/s11010-022-04411-6</a></p>2022-11-22T21:13:52ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1007/s11010-022-04411-6https://figshare.com/articles/journal_contribution/Empagliflozin_inhibits_angiotensin_II-induced_hypertrophy_in_H9c2_cardiomyoblasts_through_inhibition_of_NHE1_expression/21597393CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215973932022-11-22T21:13:52Z |
| spellingShingle | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression Nabeel Abdulrahman (725914) Biochemistry and cell biology Medical biochemistry and metabolomics Cell Biology Clinical Biochemistry Molecular Biology General Medicine |
| status_str | publishedVersion |
| title | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| title_full | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| title_fullStr | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| title_full_unstemmed | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| title_short | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| title_sort | Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression |
| topic | Biochemistry and cell biology Medical biochemistry and metabolomics Cell Biology Clinical Biochemistry Molecular Biology General Medicine |